My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Ataluren (PTC124)
    Ataluren (PTC124)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1688
    CAS #: 775304-57-9Purity ≥98%

    Description: Ataluren (also known as PTC124) is a novel, potent and orally bioavailable CFTR-G542X nonsense allele inhibitor that selectively induces ribosomal read-through of premature but not normal termination codons with EC50 of 0.1 μM in HEK293 cells, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation). Ataluren is currently being investigated for use in patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) and cystic fibrosis (nmCF). 

    References: Nature. 2007 May 3;447(7140):87-91; Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2064-9. 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)284.24
    FormulaC15H9FN2O3
    CAS No.775304-57-9
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 57 mg/mL (200.5 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Solubility (In vivo)1% DMSO+30% polyethylene glycol+1% Tween 80: 30mg/mL
    SynonymsPTC124; PTC 124; PTC-124; Ataluren.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Compared with Gentamicin which is only active at much higher concentrations, PTC124 is a more potent nonsense-suppressing agent and exhibits 4- to 15-fold stimulation of read-through relative to controls. PTC124 (0.01-3 μM) promotes dose-dependent read-through of all three nonsense codons in HEK293 cells harboring LUC-190 nonsense alleles with the highest read-through at UGA, followed by UAG and then UAA, but it does not suppress multiple proximal nonsense codons. Like Gentamicin, PTC124 is most active when a pyrimidine (in particular cytosine, C) follows the nonsense codon. Consistent with the stable cell line reporter assay, PTC124 (17 μM) promotes significant production of dystrophin in primary muscle cells from Duchenne muscular dystrophy (DMD) patients or MDXMDX mice expressing dystrophin nonsense alleles. PTC124 selectively promotes ribosomal read-through of premature termination but not normal termination codons, even at concentrations substantially greater than the values achieving maximal activity.


    Cell Assay: Cultured HEK293 cells harbouring UAA, UAG or UGA LUC-190 nonsense alleles were treated with increasing concentrations of PTC124 for 16 h, and assayed for luciferase activity. PTC124 promoted dose-dependent readthrough of all three nonsense codons. Levels of suppression correlated inversely with established termination efficiencies, with the highest readthrough at UGA, followed by UAG and then UAA. The minimal concentration of PTC124 showing discernable readthrough was 0.01–0.1 μM, whereas the concentration promoting maximal activity was approximately 3 μM.

    In VivoDue to functional recovery of dystrophin production, oral, intraperitoneal or combined dosing of PTC124 for 2-8 weeks partially rescues functional strength deficit in dystrophic muscles of MDX mice, and results in partial protection against contraction-induced injury in the extensor digitorum longus (EDL) muscles, as well as significant reductions in serum creatine kinase values. In Cftr-/- mice expressing a human CFTR-G542X transgene, subcutaneous or oral administration of PTC124 (~60 mg/kg) suppresses the G542X nonsense mutation in a dose-dependent manner, leading to a significant restoration of human (h)CFTR protein expression and function without any effect on nonsense-mediated mRNA decay (NMD) or other aspects of mRNA stability. PTC124 treatment (60 mg/kg) restores 29% of the normal intestinal transepithelial cAMP-stimulated shortcircuit currents observed in Cftr+/+ mice, displaying a significant advantage compared with Gentamicin. 
    Animal modelCftr-/- hCFTR-G542X transgenic mice 
    Formulation & DosageDissolved in DMSO, and diluted in saline; 60 mg/kg/day; s.c. injection or oral administration 
    ReferencesNature. 2007 May 3;447(7140):87-91; Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2064-9. 


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Ataluren (PTC124)

    Immunofluorescence of hCFTR in the submucosal glands of intestinal tissues from mice fed a liquid diet containing PTC124. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2064-9.
     

    Ataluren (PTC124)

    RT-PCR detection of hCFTR mRNA in untreated Cftr−/− hCFTR-G542X mice and Cftr−/− hCFTR-G542X mice treated with an oral dose of 0.9 mg/ml PTC124. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2064-9.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?